Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A notice about the NIH website terminology transition appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T21:57:18.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-06T21:49:09.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    - Core study documents (Statistical Analysis Plan; Study Protocol) were removed from the Study Documents section, reducing access to essential methodological and regulatory details. - The page now displays a 403 Forbidden error, indicating the page is currently inaccessible.
    Difference
    19%
    Check dated 2026-09-22T23:45:15.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    Revision: v3.7.0 has been added, replacing the previous v3.6.6, indicating an update to the page's version tag in the metadata.
    Difference
    0.0%
    Check dated 2026-09-15T23:29:17.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page's revision label changed from v3.6.5 to v3.6.6, indicating a minor metadata update rather than a substantive modification to the study details.
    Difference
    0.0%
    Check dated 2026-09-01T20:42:31.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The study record gains an NIH grant/contract annotation for 2015 in the list of other study identifiers, placed with the MM-398-07-02-03 and EudraCT numbers. This adds funding metadata to the record without altering the study’s design or eligibility.
    Difference
    0.0%
    Check dated 2026-08-25T20:58:07.000Z thumbnail image

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.